Medium-dose OCU410 met the 12-month primary endpoint, reducing GA lesion growth by 31% versus control (P < .05), with ...

ELIOS achieved statistically significant, clinically meaningful IOP lowering, meeting both co-primary endpoints for responder ...

NMPA authorization establishes a first-in-region, mechanism-based option for Demodex blepharitis in Greater China, where ...

In this episode of “iOpeners” from Ophthalmology Times, host Nicole Bajic, MD, comprehensive ophthalmologist at the Cole Eye Institute, Cleveland Clinic, speaks with Emily Schehlein, MD, about efforts ...

What it is. AXPAXLI (OTX-TKI) is an investigational, bioresorbable intravitreal hydrogel implant designed to continuously ...

BCVA can remain deceptively stable until late RP and becomes insensitive at profound vision loss, motivating performance-based endpoints that map to mobility and object recognition. Enrollment ...

Orphan designation reflects unmet need in RP rather than evidence of efficacy, while offering development incentives and ...

Alcon agreed to buy LENSAR for $14.00/share cash, integrating ALLY, Streamline, and the legacy laser system to expand FLACS ...

Tattoo-associated uveitis was once considered rare; however, that appears to be no longer true, according to a new Australian ...

The 51 st annual American Association for Pediatric Ophthalmology and Strabismus (AAPOS) meeting will convene from March 18 ...

Their Perspective article, published in npj Digital Medicine, warns that treating medical artificial intelligence (AI) as an ...

Following a second injection at eight weeks, the patient maintained stable vision and remained dry at 12 weeks, allowing for ...